Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
A Multi-Center Phase I/II Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor: Endeavor Health
A PHASE1/PHASE2 clinical study on Hodgkin's Disease and Lymphoma, this trial is completed. The trial is conducted by Endeavor Health and has accumulated 14 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1/PHASE2
-
Mar 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
▶ Show 9 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Jun 2022 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE1_PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1_PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Mar 2017 — Dec 2017 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Endeavor Health
- Memorial Sloan Kettering Cancer Center
- Merck Sharp & Dohme LLC
- Northwestern University
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .